Yahoo
NasdaqGM - Nasdaq Real Time Price USD

ANI Pharmaceuticals, Inc. (ANIP)

73.04 +1.33 (+1.85%)
As of 12:35:28 PM EDT. Market Open.
Trade ANIP on Coinbase
Chart Range Bar
Loading chart for ANIP
  • Previous Close 71.71
  • Open 72.68
  • Bid 56.91 x 200
  • Ask 103.53 x 200
  • Day's Range 72.05 - 73.62
  • 52 Week Range 69.58 - 95.57
  • Volume 54,899
  • Avg. Volume 385,475
  • Market Cap (intraday) 1.678B
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) 15.81
  • EPS (TTM) 4.62
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 105.78
  • Motley Fool Rating Bullish

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

www.anipharmaceuticals.com

970

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ANIP
7.48%
S&P 500 (^GSPC)
12.67%

1-Year Return

ANIP
20.81%
S&P 500 (^GSPC)
11.93%

3-Year Return

ANIP
24.04%
S&P 500 (^GSPC)
87.33%

5-Year Return

ANIP
95.39%
S&P 500 (^GSPC)
67.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 266.04M
Earnings 24.71M
Profit Margin 9.29%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
150M
200M
250M
10.0%
11.0%
12.0%

Analyst Insights

View More

Analyst Price Targets

85.00
105.78 Average
73.04 Current
121.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/23/2026
Analyst Oppenheimer
Rating Action Initiated
Rating Perform
Price Action Announces
Price Target 85

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.07%

  • Return on Assets (ttm)

    5.45%

  • Return on Equity (ttm)

    20.46%

  • Revenue (ttm)

    978.38M

  • Net Income Avi to Common (ttm)

    99.6M

  • Diluted EPS (ttm)

    4.62

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    376.96M

  • Total Debt/Equity (mrq)

    104.82%

  • Levered Free Cash Flow (ttm)

    132.21M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: